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ABSTRACT
A PRELIMINARY INVESTIGATION OF THE STERILE-FILTERABILITY OF
BCS CLASS II DRUG NANOSUSPENSIONS PREPARED VIA WET STIRRED
MEDIA MILLING
by
Parul Ohri
Drug nanoparticles can achieve targeting capabilities, enhanced dissolution rates and
improved bioavailability when injected intravenously. Sterile filtration of drug
nanoparticle suspensions (nanosuspensions) is critically needed for administration by
intravenous delivery route. Avoiding gamma irradiation and high temperatures, sterile
filtration could be an effective process to sterilize drug nanosuspensions. On the other
hand, two major challenges must be tackled: drug particles must at least be smaller than
the filter pore size and minimum amount of non-toxic stabilizers must be used to prevent
side effects like pain on the injection site. The aim of this study is to prepare naproxen
(NPX) nanosuspensions via wet stirred media milling using various polymers and
surfactants as stabilizers and to assess their physical stability with the ultimate goal of
achieving the sterile filterability of such produced suspensions. An intensified milling
process was investigated for fast production of sub-200 nm drug particles. In the second
part, various formulations to stabilize NPX nanoparticles were screened. Lastly, the
suspensions with NPX particle size less than 220 nm were filtered through a sterile 0.22
μm disposable capsule filter. Laser diffraction, scanning electron microscopy, rheometry,
and surface tension measurement were used to evaluate the breakage kinetics and storage
stability. Although NPX nanosuspensions were stabilized using stabilizers acceptable for
injection, their sterile filtration was not successful, indicating a critical need for further
research regarding the use of acceptable stabilizers and filter type/processing.
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CHAPTER 1
INTRODUCTION
1.1

Objectives

The goal of this exploratory and preliminary study is to assess the sterile filterability of
Biopharmaceutical Classification System (BCS) Class II drug nanosuspensions, which
are prepared via wet stirred media milling (WSMM). To achieve this goal, the thesis has
the following specific objectives: (a) to explore the impact of process parameters on the
final product nanosuspensions, (b) to study the impact of various stabilizers, i.e.,
polymers and surfactants, to impart physical stability against aggregation of drug
nanoparticles present in the milled aqueous suspension, and (c) to filter the drug
nanosuspensions which have D90 less than 220 nm through a sterile vacuum filter using
four different membranes.

1.2

Background Information

1.2.1 Bioavailability Enhancement of Poorly Water-Soluble Drugs
The bioavailability enhancement of BCS Class II (poorly water soluble) drugs can be
achieved by (a) increasing the surface area of drug crystals by particle size reduction
(Noyes and Whitney, 1897); (b) use of pro-drug and drug derivatives such as strong
electrolyte salt forms that usually have higher rate of dissolution (Liu et al. 2006); (c)
microemulsions which have been employed along with incorporation of proteins to
increase solubility of drugs (Ashwini et al. 2014); (d) micellar solubilization, which
involves use of surfactants to lower surface tension and improve the dissolution
performance of poorly soluble drug products (Carvalho et al. 2010); (e) complexation of
1
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drugs, which has been used to enhance aqueous solubility and drug stability (Meyer et al.
1998); (f) decreasing crystallinity of drug substance through formation of solid
solutions/amorphous solids (Kim et al. 2008, Shen et al. 2010, Zhang et al. 2006); and (g)
formation of water-soluble complexes (Jansook et al. 2010).

1.2.2 Methods for Producing Drug Nanosuspensions
Among various methods for enhancing the bioavailability of BCS Class II drugs, size
reduction of the drug crystals to the nanometer scale has been identified to be a promising
approach (Kondo et al. 1993, Liversidge et al. 1996). According to the Nernst–Brunner
equation, particle size reduction increases the specific surface area enhancing the
dissolution rate, which in turn improves the bioavailability of poorly water-soluble BCS
class II drugs (Noyes and Whitney, 1897, A. Dokoumetzidis et al. 2006). As smaller
particles dissolve faster, it is expected that drug nanoparticles with very large surface area
could significantly enhance the dissolution rate, thus allowing for sufficiently high
bioavailability for some of the BCS Class II drugs.
There has been a growing interest in the production of drug particles in the size
range 50-200 nm in a reproducible manner (Niwa et al. 2011, Juhnke et al. 2010). The
manufacturing of a drug nanosuspension leads to the formation of nanoparticles with
higher surface area and interface (Eerdenbrugh et al. 2008). Preparation of
nanosuspensions involves adoption of two general approaches: bottom-up approach
(forming nanoparticles from molecules) and top-down approach (size reduction). The
best example of a bottom-up approach is anti-solvent precipitation/crystallization (Sinha
et al. 2013). Anti-solvent precipitation involves the addition of drug solution to a solvent
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precipitating the drug (the solvent known as non-solvent), which further controls the
crystallization of drugs by presence of certain stabilizers in the non-solvent phase (Thorat
et al. 2013). Due to the constraints in the bottom-up approach during scale-up, the topdown approach has been commonly used as a promising technique for producing
nanosuspensions (Ghosh et al. 2011). In the top-down approach, various wet milling
techniques such as media milling, high-pressure homogenization (HPH), etc. have been
used. Among these techniques, size reduction of drug crystals to a nanometer scale via
wet stirred media milling has been determined to be a promising approach to boost
bioavailability (Kondo et al. 1993, Liversidge et al. 1996). Typically, 100–500 nm
particles were prepared by several hours of milling with relatively high-energy
consumption (Bose et al. 2012, Cerdeira et al. 2010, Knieke et al. 2013). The process of
media milling consists of mechanical attrition of drug particles using milling media such
as yttrium stabilized zirconium oxide beads of definite size range (Van Eerdenburgh et al.
2008). High-pressure homogenization has also been used because of its reduced product
contamination (Keck and Muller, 2006). The mean particle size of nanosuspensions
prepared by HPH is usually between 400 nm and 1000 nm (Lou et al. 2011, Wang et al.
2011, Xiong et al. 2008).

Wet stirred media milling (WSMM) has proved to be a robust top-down approach
for producing nanosuspensions of poorly water-soluble drugs (Bhakay et al. 2011, Bruno
et al.1996, Merisko-Liversidge et al. 2003) due to its universal applicability to all BCS
Class II drugs, solvent-free/environmentally benign operation, capability to handle high
drug loading, and scalability (Afolabi et al. 2014). Unlike other milling methods, WSMM
can produce drug nanoparticles down to 50-200 nm particles or larger in a
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pharmaceutical industry (Sinha et al. 2013). A cursory review of recent literature, which
is not intended to be comprehensive, on finely milled BCS Class II drugs via WSMM is
presented in Table 1.1. The data support the commonly held notion that fast preparation
of drug suspensions with a D90 particle size below 220 nm particle size is extremely
challenging.

Table 1.1 Recent Literature on Drug Nanosuspensions Prepared via Wet Stirred Media Milling (WSMM)
Drug
Drug
Batch Size Bead
Milling Time Final
Final
References
(ml)
(min)
Loading
Size
Median
Particle
(% w/w)
(μm)
Size, d50
Size, d90
(nm)
(nm)
b
a
Naproxen
5
12
300
240
200
Bitterlich et al.
NR
2015
Naproxen

10

400b

200

64

143

238

Naproxen

1

10c

NR

a

60

NR

a

207

Monteiro et al.
2013
Sumit et al. 2014

Naproxen

5

NR

200

60

NR

a

<500

George et al. 2013

Iodipamide

15

1000

8001000

5-10d

98

<220

Zheng et al. 1997

Indomethacin

20

10

1000

21

NR

345

Liu et al. 2011

Indomethacin

NR

50

NR

a

30

200

2370

Sharma et al. 2009

Fenofibrate

2.5

200

400

60

460

960

Knieke et al. 2013

Naproxen

10

200

400

90

144

230

Sievens et al. 2012

Griseofulvin

10

200

400

64

163

211

Bilgili et al. 2012

a

a

a

a

Not Reported.
Volume of water (ml) used in the suspension.
c
Mass (mg) of the suspension.
d
Days of ball milling.
b

5
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Wet stirred media milling (WSMM) involves the use of micron-sized drug
particles and media (beads) in an aqueous solution of dissolved stabilizers usually
polymers and/or surfactants, which are mixed by a stirrer (rotor) at a very high speed.
The micron-sized drug particles are captured between the colliding beads due to repeated
stressing caused by milling continued for adequate time. Production of nanosuspensions
creates new interfaces resulting in positive Gibbs free energy. As a result, these
nanosuspensions are thermodynamically unstable and undergo aggregation of particles,
which leads to decrease in interfacial tension (Wu et al. 2011, Van Eerdenbrugh et al.
2008). This problem can be dealt by wetting the hydrophobic surfaces of the drug
particles on addition of stabilizers, which increases the activation energy of the
aggregation process (Verma et al. 2009). Therefore, proper selection of stabilizers is
mandatory. Stabilizers are added to prevent the aggregation of milled drug particles and
to inhibit particle growth (ripening) during milling/storage. Dissolution and in vivo
performance may be affected by aggregation of the milled drug particles, which can be
prevented by addition of stabilizers (Ghosh et al. 2011, Kesisoglou et al. 2007). An
optimal stabilizer type/concentration, which ensures proper short- and long-term physical
stability of a drug nanoparticle suspension, is usually obtained by stabilizer screening
studies at the bench-scale (Kesisoglou et al. 2007, Van Eerdenbrugh et al. 2008).

Nanosuspensions are stabilized via steric and/or electrostatic mechanisms
imparted by the use of various stabilizers. Steric stabilization is attained by adsorbing
polymers onto the drug particle surface; whereas electrostatic stabilization is achieved by
adsorbing charged molecules, both ionic surfactants and charged polymers, onto the
particle surface (Van Eerdenbrugh et al. 2009). Thus, the mechanism of stabilization is

7
contributed by both the physical properties of stabilizers and surface properties of the
drug (Figure 1.1). The application of a proper stabilizer considers several factors:(a)
polymer length and molecular weight of a polymer achieves a thermodynamic driving
force for physical adsorption on the surface of the particle, (b) molecular weight of a
polymeric stabilizer is inversely proportional to the rate of adsorption, (c) high
concentration of long change polymers may lower the dissolution rate. Surfactants should
be sparingly used in the pharmaceutical applications to lessen or diminish the unfavorable
impacts:


Aggregation of drug nanoparticles in suspension during milling or storage above
critical concentration (Cerdeira et al. 2010).



Micellar solubilization (Seedher et al. 2008), and size growth during Ostwald
ripening (Knieke et al. 2013, Verma et al. 2011).



Toxicity (Liversidge et al. 2005) caused if used in excess especially in inhalation
products (Lebhardt et al. 2011, Suzuki et al. 2000).



Causing gastric and pulmonary irritation (Oberle et al. 1995).

8

Figure 1.1 The mechanism of stabilization of the milled drug particles during the media
milling process.
Source: George, M. & Ghosh, I. (2013), European Journal of Pharmaceutical Sciences

1.2.3 Applications of Nanosuspensions in Intravenous Administration Route
Nanosuspension is a carrier-free nanoparticle system containing only pure drug crystal
and minimum surfactant and/or polymer dissolved in water for stabilization (Keck &
Müller, 2006). Nanosuspension could greatly increase drug dissolution rate; this
important feature renders it an excellent strategy to deal with BCS Class II and IV drugs
(Müller et al. 2001, Rabinow, 2004, Kesisoglou et al., 2007). Routes of administration of
drugs are generally classified as enteral and parenteral. Enteral route of administration
deals with the GI tract and includes oral, buccal, and rectal route. Parenteral routes of
drug delivery commonly refers to injectable such as intravenous (IV), intramuscular
(IM), and subcutaneous (SC) but could also include topical and inhalation. Drug
undergoes either first-pass metabolism or is not absorbed through the gastrointestinal
tract in enteral route of administration. Consequently, the bioavailability after oral
administration can be poor and very often below the therapeutic level. Intravenous
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administration could provide greater bioavailability and is an alternative to oral
administration (Xiong et al. 2008). All other categories of injections except IV must cross
one membrane, involving an absorption process in the administration. As compared to
other dosage forms, IV administration route offers many advantages:


Quick onset of action in case of emergency.



Reduction in dose of the drug and the ability to target the drug quickly to the
desired site of action, especially in the case of severe infections.



Control over dose and rate allows more predictable pharmacokinetic profiles.



Control of plasma concentration.



Bioavailability is generally 100% as the whole dose is delivered to the blood
stream.



Larger doses of poorly soluble drugs may be given in larger volume by IV
infusion over an extended time.

There is a considerable limitation in use of intravenous route due to harmful
solvent and excipients, which can cause serious side effects other than the drug itself
(Wang et al. 2011, Rabinow et al. 2007). Moreover, a prerequisite for the IV injection of
suspensions is a small particle size, i.e. preferentially in the nanometer range with little
content of microparticles (Muller et al. 1998). The microparticles lead to toxic effects and
ultimately to emboli when they exceed a critical level in the administered dose (Davis
and Traube, 1978, Schroeder et al. 1978, Slake et al. 1981). Thus, size range of ≤100 nm
is preferred for parenteral nanocrystals (Jinno et al. 2006). Under such circumstances,
nanocrystals could be considered as the ideal candidates for intravenous delivery
provided their formulation does not employ excess use of such harmful excipients.
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1.2.4 Process Intensification
Process intensification of WSMM process targets for faster production of particles below
220 nm of BCS Class II drug particles. Drug particle sizes less than 220 nm may allow
for successful sterile filtration. Despite previous experimental studies focusing on the
impact of various process and formulation parameters on the milled particle size (Afolabi
et al. 2014, Cerdeira et al. 2011, Ghosh et al. 2011, 2012, 2013, Monteiro et al. 2013,
Singare et al. 2010, Singh et al. 2011), only Li et al. (2015) reduced milling time and
energy consumption, while keeping media contamination low via intensification of
process parameters such bead loading, rotor speed, and suspension flow rate upon use of
optimal bead size.

1.2.5 Sterilization of Drug Nanosuspensions
Sterilization of drug nanosuspensions is critically intended for administration by
intravenous injectables. This can be achieved by termination sterilization (e.g.,
autoclaving, sterile filtration, and gamma irradiation) of finished products or aseptic
processing that is very costly. Autoclaving can lead to particle aggregation and thermal
degradation of the drug due to use of high temperatures (Torchilin et al. 2006). Similarly,
gamma irradiation can degrade the stabilizing polymers leading to particle aggregation
and generate impurities along with the sterilization validation concerns (Torchilin et al.
2006). Therefore, autoclaving and gamma irradiation are non-preferred processes for
sterilization of drug nanosuspensions. While drug solutions can be sterilized commonly
using the techniques mentioned here, only few drug nanosuspensions have been sterilized
using these techniques, mainly the aseptic processing (Alekha et al. 2014). A platform
technology for sterilizing drug nanosuspensions besides the costly aseptic processing
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does not exist. Hence, assessment of the sterile filtration of drug nanosuspensions is
warranted, and is the goal of the present study.

Filtration is aimed at sterilizing a drug solution or nanosuspension by removing
microorganisms, which is followed by aseptic packaging. Unfortunately, drug
suspensions pose a particular challenge: particles larger than the pore openings cannot
pass through the filter and are retained on the surface of the filter (Grace H. P., 1956). An
appropriate sterilizing grade filter is one that reproducibly removes all microorganisms
from the process stream, producing a sterile effluent (Zheng et al.1997). Generally,
capsule configurations of vacuum sterilizing grade filters, which are sterilized by gamma
irradiation, are used. The total time for product filtration should be limited to established
maximum to prevent microorganisms from penetrating the filter and to prevent a
significant increase in upstream bioburden and endotoxin load (S. Niazi et al. 1949).
Factors that can affect filter performance commonly include (a) viscosity of the material
to be filtered, (b) pH, (c) compatibility of the material or formulation components with
filter itself, (d) pressures, (e) flow rates, (f) maximum use time, (g) temperature, (h)
osmolality, (i) and the effect of hydraulic shock (Jornitz et al. 2006).

Most applications make use of filters made of cellulose esters, polyvinyl fluoride,
polytetrafluoroethylene, nylon and other polymeric materials (Mckinnon et al. 1993).
Membrane filters constitute of two types of membranes:


Hydrophobic (‘water-disliking’) for use with gas filtration, in which
compounds are repelled by water and are usually neutral, and
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Hydrophilic (‘water-liking’) for use with liquid filtration, in which compounds
have affinity to water and are usually charged or have polar side groups to
their structure that will attract water.

The membrane filters must be fully compatible with the chemical characteristics
of the nanosuspensions due to filter membranes containing non-toxic wetting agents that
may interfere with some applications. Moreover, other membranes may bind proteins or
other macromolecules, which may lead to premature filter clogging or loss of valuable
samples. Therefore, it is very important to understand their characteristics and the
potential effects filter membranes can have on the solutions they contact. The varying
membranes used in sterile filters are as follows:


Cellulose Acetate (CA) membranes have low binding affinity, low chemical
resistance, and are naturally hydrophobic. Furthermore, these membranes
have small amounts (less than 1%) of non-toxic wetting agents to ensure
proper wetting of the membrane (Corning Storage Bottles Selection and Use
Guide).



Polyethersulfone (PES) membranes have faster flow rates. These membranes
are without wetting agents and have low chemical resistance (Corning
Filtration Guide).



Polyvinylidene fluoride (PVDF) membrane has high flow rates; ultra-low
binding properties, and broad chemical and temperature resistance
(Polyvinylidene Fluoride (PVDF) Membrane).
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Polyamide (PA) membrane is mechanically very strong and exhibits
excellent wet strength and dry strength. Also, these are hydrophilic making
them suitable for aqueous and organic solutions (Polyamide Membranes).

1.3

Organization of Thesis

Chapter 2 describes the experimental details of the study, including methods and
materials for suspension and different filter membranes used, as well as methods for
product characterization. Results and discussion of the impact of process parameters,
different polymer and surfactant concentrations, different polymers and surfactants, and
filtration studies are presented in Chapter 3. Chapter 4 presents a summative assessment
of potential polymers and surfactants, stabilizing NPX nanosuspensions with an objective
to achieve a particle size under 220 nm. Chapter 5 discusses potential future work.

CHAPTER 2
EXPERIMENTAL

The methods of preparing and characterizing naproxen nanosuspensions are given in this
chapter. Naproxen nanosuspensions were prepared via wet stirred media milling and their
particle size, viscosity, and surface tension were characterized. The milled drug
nanosuspensions with a final D90 particle size below 220 nm were sterile filtered using
capsule filter with four different membrane materials.

2.1 Preparation of Naproxen Nanosuspensions

2.1.1 Materials
WSMM experiments were carried out on the poorly water-soluble drug naproxen (NPX).
Naproxen is a proprionic acid derivative related to the arylacetic acid group of
nonsteroidal anti-inflammatory drugs (FDA). Figure 2.1 shows the chemical structure of
NPX, which has a molecular weight of 230.26 Da and is practically insoluble in water.
NPX is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic
properties. Naproxen is rapidly and completely absorbed from the gastrointestinal tract
with an in vivo bioavailability of 95%; hence, it serves as a model BCS Class II drug.

Figure 2.1 Chemical structure of naproxen.
Source: www.chemspider.com

The absorption of drugs with poor aqueous solubility like NPX is dissolution rate limited
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and therefore, they exhibit poor bioavailability resulting in multiple dosing of drug as
well as fluctuation in blood concentrations (Medina et al. 2015).

To stabilize the drug particles during milling and storage, different stabilizers
were used in the suspensions. The physicochemical properties of different stabilizers are
presented in Table 2.1
Table 2.1

Properties of Stabilizers Used in Wet Stirred Media Milling

PVP 12

Solubility at 25 oC
(mg/mL)
0.17

Molecular weight
(Da)
2000-3000

Melting Point
(oC)
120

PVP 17

0.17

7000-11000

126

P188

>10%

7680-9510

52

P407

>10%

9840-14600

56

Tween 20

100

1225

56-58

Tween 80

50-100

1310

-21

HPC SL

20

100000

180-220

SDS

150

288.38

206

Soluplus

0.03

118000

166

HPMC E3

50

86000

190-200

Stabilizers

16

2.1.2 Preparation Methods
Table 2.2 presents the suspension formulations used in this study. Feed NPX
suspensions were prepared using a shear mixer (Cat#. 14-503, Fisher Scientific,
Pittsburgh, PA, USA) running at a fixed speed of 300 rpm. To find an efficient process
condition for fast production of drug particles, in Runs 1-3, HPC (SL grade)-SDS
combination which provides sufficient stabilization for various drug nanoparticles
such as griseofulvin, was selected based on our previous work (Bilgili & Afolabi,
2012). Firstly, 2.5% HPC SL was added to deionized water in a beaker gradually for
15 min while the mixer ran at a fixed speed of 300 rpm for 15 more min. Then, 0.5%
SDS was added to the HPC SL solution gradually for 5 min and led to mix for 10 more
min. All percentages (%) used throughout the preparation refer to w/w with respect to
deionized water. The final HPC SL–SDS solution was further mixed for 15 min to
ensure proper dissolution of HPC SL and SDS particles. For formulations wherein a
single stabilizer was used (Runs 4-20), the stabilizer was added in 15 min and allowed
to mix for another 15 min to ensure that the stabilizer is fully dissolved. Desired
amount of NPX powder (10%) was weighed and added to the stabilizer solution
gradually for 30 min while mixing continued.

Table 2.2 Stabilizer Percentages for Each Run in WSMM
Run
Stabilizer
4

PVP 17

Concentration
(% w/w)
0.5

5

PVP 17

2.5

6

PVP 12

2.5

7

PVP 17

5

8

PVP 17

10

9

HPC SL

2.5

10

HPMC E3

2.5

11

Soluplus

2.5

12

P188

0.5

13

P188

2.5

14

P188

5

15

P188

10

16

P407

2.5

17

Tween 20

2.5

18

Tween 20

5

19

Tween 80

2.5

20

Tween 80

5

17

18

Figure 2.2 Schematic of the Netzsch stirred media mill (Model: Microcer) operating in
the recirculation mode. P and T stand for Pressure Gauge and Thermocouple,
respectively.
Source: Bhakay, A., Davé, R., & Bilgili, E. (2013), Powder Technology.

Drug suspensions were subsequently milled in a Netzsch wet media mill
(Microcer, Fine Particle Technology LLC, and Exton, PA, USA). The wet stirred media
milling process is depicted in Figure 2.2. The milling chamber is lined with zirconia and
has a volume Vm of 80 ml. In this so-called recirculation mode, each feed suspension was
poured into the holding tank and was recirculated between the holding tank and milling
chamber at a constant volumetric flow by a peristaltic pump. The suspensions were
milled for 64 min, which allowed sufficient time for preparation of NPX nanoparticles.
Milling media (beads) are inside the milling chamber and set into motion by the rotation
of the rotor. A turbulent motion was induced in the suspension by the high speed rotor,
and turbulent energy dissipates during frequent bead–bead collisions (Eskin et al. 2005),
causing extensive breakage of drug particles captured between the beads (Bhakay et al.
2011, Bilgili et al. 2006). Yttria-stabilized zirconia beads with a nominal size of 100 µm
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were used as the milling media. A screen with 50 μm nominal opening size, located at the
outlet of the milling chamber, retained the zirconia beads, while allowing the passage of
the drug suspension. Both the milling chamber and the holding tank are equipped with a
chiller unit (model number M1-25A-11HFX, Advantage Engineering, Green-wood, IN,
USA) which kept the suspension temperature in the holding tank below 35°C, as a
maximum. The stirrer was stopped occasionally followed by intermittent cooling when
the temperature reached 35°C due to high heat generation rate. Samples were taken from
the outlet of the milling chamber at several intervals of milling. The final suspensions
(after 64 min milling) were tested for density and shear viscosity, and they were
refrigerated at 8◦C for a period of 7 days. Particle sizes right after milling and after 7 days
of storage were compared to assess the physical stability of the suspensions.

Based on the process intensification approach proposed by Li et al. (2015), the
process parameters were varied from the baseline (Run 1) first by reducing the bead size
(Run 2) and then increasing the rotor tip speed, bead loading, and suspension flow rate
simultaneously (Run 3), with the objective of achieving fast production of drug particles
less than 200 nm in D90 (refer to Table 2.3 for the parameters). The process parameters
for Run 3, the intensified process, were then adapted for the rest of this study, where the
impact of various stabilizers was investigated under the most intense milling conditions.
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Table 2.3 Effect of Process Parameters Investigated in the Wet Milling Experiments
Bead Loading, Bead Size
Run Milling
Pump Speed
(g)
(μm)
(mL/min)
Speed
(rpm)
1

3200

196

400

126

2

3200

196

100

126

3

4000

261

100

343

Figure 2.3 Experimental set-ups for the sterile filtration process.
2.2 Sterile Filtration of Nanosuspensions
Filtration experiments of stabilized NPX nanosuspensions were performed at room
temperature using polyvinylidene difluoride (PVDF), polyethersulfone (PES), cellulose
acetate (CA), and polyamide (PA) vacuum membrane filters (Corning Incorporated Life
Sciences, MA, USA) as shown in Figure 2.4, having a pore diameter of 0.22 μm;

21
membrane area of 19.6 cm2; and volume of 250 ml. A sterile filter is connected to the
vacuum line and the nanosuspension was poured from the top on the filter membrane.
30 g NPX nanosuspension was passed through sterile filters with four different
membranes. All the drug particles larger than the surface opening or pore size are
retained at or near its surface.

Figure 2.4 Sterile vacuum filters used for sterile filtration of NPX nanosuspensions.
Source: Innovative Products for Filtration and Ultrafiltration” Corning Filtration Guide.

2.3 Characterizations
2.3.1 Particle Size Distribution
Particle size analysis of the milled suspensions was performed by laser diffraction using a
Beckmann Coulter LS230. A polarized intensity differential scattering (PIDS)
obscuration water optical model was employed. The PIDS was maintained between 40%
and 50% while the obscuration was maintained 8% for all particle size measurements. A
refractive index (RI) value of 1.61 for the NPX particles (Kean WF et al. 1989) and 1.33
for the measurement medium (DI) water were used. Prior to the size measurement, milled
suspension samples (~2 ml) were diluted with 5 ml of stabilizer solution. The refrigerated
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suspension samples after 7-day storage were stored in room temperature for 30 min and
then mixed via a digital vortex mixer (Thermo Fisher Scientific Inc., USA) at 1500 rpm
for 1 min. ~2 ml samples were taken and diluted for particle size measurement using the
same stabilizer solution as in the suspensions. Suspensions after filtration process were
also tested for particle sizes immediately after filtration and after 7-day storage following
the procedures above.
2.3.2 Apparent Shear Viscosity
The apparent shear viscosity of the milled suspensions was measured using an R/S plus
rheometer (Brookfield Engineering, Middleboro, MA, USA) with a water jacket
assembly Lauda Eco (Lauda-Brinkmann LP, Delran, NJ, USA). A coaxial cylinder (CC
40) was used to impart controlled shear rate on the samples from 0 to 1000 1/s in 60 s.
The temperature of the jacket was kept constant at 25 ± 0.2 oC. The raw data were
analyzed using the Rheo 3000 software (Brook-field Engineering, Middleboro, MA,
USA) of the R/S plus rheometer to obtain the apparent shear viscosity.
2.3.3 Surface Tension
The surface tension of the final HPC–SDS solution or HPC solution and milled
suspensions was measured using Attension Sigma 700 (Biolin Scientific, Linthicum, MD,
USA). The Attention calculates surface tension from force measurements of interaction
of a probe (Wilhelmy plate) at the boundary between air and a liquid.
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2.3.4 Scanning Electron Microscopy (SEM)
Particle size and morphology of the as-received and milled drug particles were examined
via SEM with a LEO 1530 SVMP (Carl Zeiss, Inc., Peabody, MA, USA). About 0.1 ml
of the milled suspension was diluted with 30 ml de- ionized water, and a drop was placed
on a silicon chip (Ted Pella, Inc., Redding, CA, USA), dried, sputter coated, and
observed in SEM.
2.3.5 X-Ray Power Diffraction (XRD)
The crystallinity of the as-received drug, unmilled physical mixture (overnight dried
aqueous suspension with as-received drug and PVP 17), and overnight dried, milled
suspensions was analyzed using X-ray Powder Diffraction (XRD, PANalytical, Westborough, MA, USA), provided with Cu Kα radiation (λ = 1.5406 Å). The samples were
scanned for 2θ ranging from 5° to 40° at a scan rate of 0.165 s-1.
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CHAPTER 3
RESULTS AND DISCUSSIONS
3.1 Impact of Process Intensification

3.1.1 Impact of Bead Size
NPX particles were wet-milled using beads with two different nominal sizes: 400 and
100 μm in Runs 1-2. Understanding the impact of bead size is crucial for subsequent
process intensification of the most milling process (Li et al. 2015). 90% passing size (d90)
obtained in Run 2 with 100 μm beads was 195 nm, which is slightly smaller than the one
obtained in Run 1 with a particle size of 229 nm with 400 μm beads (Table 3.1). Smaller
beads have higher frequency of bead-bead collisions and drug particle compressions
despite potentially decreased maximum contact pressure (Li et al. 2015). Besides, wear of
100 μm beads is expected to be lower than 400 μm beads, causing lower contamination in
the milled drug suspensions (Li et al. 2015). Overall, it is suggested that the use of 100
μm beads can be advantageous for the fast production of finer NPX particles and should
be used for process intensification.

3.1.2 Impact of Increase in Bead Loading, Rotor Speed, and Flow Rate
Bead loading of 196 g was used in Runs 1-2, which produced a d90 of 195 nm in Run 2 at
the lowest. The process was intensified in Run 3 with an increase in bead loading, rotor
speed, and flow rate. The intensified milling condition was based on previous work Li et
al. (2015). With the intensified process, drug particle size was reduced to 185 nm after
milling, as shown in Table 3.1. Final particle sizes were approximately attained after 16
min. An intensified milling process increased the apparent breakage rate and led to
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smaller final particle size. There was a decrease in clearance between the beads upon
increasing bead loading. The increase in rotor speed further led to a dramatic increase in
the bead–bead collisions and drug particle compressions. When a higher suspension flow
rate was used, the breakage rate was further increased due to tighter residence time
distribution of the suspension in the mill chamber (Monteiro et al. 2012). The milling
conditions in Run 3 led to the fastest NPX breakage and were therefore used in the
following formulation studies.

Median size,d50 (µm)

10

400 µm, standard milling
100 µm, standard milling
100 µm, intensified milling

1

Particle size,d90 (µm)

0.1
10

1

0.1
10

100

Time, t (min)

Figure 3.1 Impact of process parameters: (a) the time-wise variation of the median size,
(b) the final particle size of NPX during milling. Runs 1, 2, and 3 refer to milling of NPX
with 400, and 100 μm YSZ beads respectively at the baseline process conditions (Q =
126 ml/min), and intensified process conditions (Q = 343 ml/min). At t = 0 min, NPX
particles have d50 = 15.08 ± 0.15 μm and d90 = 37.59 ± 0.01 μm.
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Table 3.1 Particle Size and Standard Deviation (SD) Obtained From Laser Diffraction
(LD) for Runs 1-3 Suspensions After Milling and After 7 days Storage
Run

d50 ± SD (µm)
After Milling

d90 ± SD (µm)
7-Day Storage

After Milling

7-Day Storage

1

0.124 ± 0.000

0.127 ± 0.001

0.229 ± 0.070

0.226 ± 0.007

2

0.122 ± 0.060

0.114 ± 0.002

0.195 ± 0.002

0.214 ± 0.015

3

0.110 ± 0.000

0.111 ± 0.001

0.185 ± 0.001

0.196 ± 0.005

A rheological characterization of the milled suspensions was performed because
the injectable formulations should have ideally low viscosity (preferably below 100 cP),
yet being physically stable. Fig. 3.2 shows that all milled suspensions had less than 50 cP
apparent shear viscosity, which is highly desirable for injectables. An addition of SDS to
an HPC SL solution increased the viscosity significantly, which can be attributed to the
formation of HPC–SDS aggregates or micelle-like SDS clusters bound to the polymer.
Such HPC–SDS interactions are expected to result in a synergistic electrostatic
stabilization (Bilgili and Afolabi, 2012).
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The lowest apparent shear viscosity of 6.7 cP was obtained at 1000 (1/s) for Run 3
in Table 3.2. The pre-suspension of 2.5% HPC SL and 0.5% SDS before milling showed
the highest values of apparent shear viscosity of 162.7 cP at 1000 (1/s) shear rate. This
and the ranking of Runs 1-3 suspensions (Table 3.2) can be explained by the fact that
suspensions with smaller particle size exhibit lower viscosity. Similar observation was
also made by Winnik and Winnik (1990), Evertsson and Nilsson (1997), and Berglund et
al. (2003). Also, the viscosity of a milled suspension was lower than that of the stabilizer
solution (Table 3.2) because of relatively well-dispersed nature of the NPX suspensions
with HPC–SDS and the reduced concentration of HPC–SDS in the bulk solution of the
NPX suspensions due to enhanced HPC SL adsorption (Bilgili et al. 2012).

1000
suspensions

Apparent Shear Viscosity (cP)

solution

400 µm, standard Milling
100 µm, standard Milling
100 µm, intensified Milling
2.5% HPC SL,0.5% SDS Presuspension

2.5% HPC SL, 0.5% SDS
100

10

10

100

1000

100

1000

Shear rate (1/s)
Figure 3.2 Log–log plots for apparent shear viscosity versus shear rate for (a) the HPC
SL solutions; (b) milled NPX suspensions.

28
Table 3.2 Apparent Shear Viscosity of the HPC SL-SDS-based Solution and Suspensions
at 25 °C and 1000 (1/s) Shear Rate
Apparent Shear Viscosity (cP)
Run
Pre-suspension (unmilled)

162.7

Stock stabilizer solution

44.5

1

20.5

2

16.2

3

6.7

Table 3.3 shows that the HPC SL–SDS solution has higher surface tension than
water (34.363 ± 0.111 mN/m) due to formation of micelle like SDS clusters bound to
HPC SL. On the other hand, the surface tensions of milled suspensions were slightly
lower than those of the corresponding stabilizer solutions because of the reduced bulk
concentration of the stabilizers in the milled suspensions. HPC SL imparts poorer
wettability to drugs in water relative to SDS even though it reduces surface tension of
water (Dalvi et al. 2010, Rasenack et al. 2003).

Table 3.3 Surface Tension for HPC SL-SDS Suspensions
Solution (mN/m)
Milled Suspension (mN/m)
Run
Mean ± SD
Mean ± SD
1
37.868 ± 0.064
34.363 ± 0.111
2

37.786 ± 0.055

36.638 ± 0.377

3

37.838 ± 0.09

36.517 ± 0.564
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3.2 Impact of Polymer Concentration

3.2.1 Particle Size of Milled Suspensions

In the absence of any stabilizer, NPX particles alone could not be milled since it is
very hydrophobic and a foam appeared during the milling and milling could not be
continued. Thus, stabilizers are needed to reduce surface tensions and prevent
aggregation. Figure 3.3 shows the evolution of the NPX particle size with different PVP
concentrations during milling. HPC-SDS combination was used as a comparative
baseline, which provides sufficient stabilization for NPX drug particles. However, HPCSDS combination cannot be used for injectables; hence, acceptable stabilizers like PVP
are being investigated here. In general, NPX nanosuspensions were successfully prepared
in the presence of PVP. The particle size decreased and attained a plateau in time; there
was no significant increase in particle size during milling and storage (Table 3.4). Hence,
PVP successfully suppressed the aggregation during the milling and storage. The effect
of PVP concentration on particle size is relatively weak; the suspensions were stable even
at low PVP concentration. A slight optimum concentration of 2.5% exists for PVP 17, in
view of the 7-day stability data (Table 3.4), while 2.5% HPC SL in presence of SDS
produced the lowest median size (d50) and 90% passing size (d90), i.e., 110 nm and 185
nm respectively, due to synergistic stabilization imparted by HPC-SDS combination.
Overall, these results suggest that stable NPX nanosuspensions can be prepared using
polymers acceptable for injectable applications; however, the sterile filterability of such
suspensions is yet to be assessed below.
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Median Size, d

50

(µm)

0.5% PVP 17
2.5% PVP 17
5% PVP 17
10% PVP 17
2.5% HPC SL,0.5% SDS

Particle Size, d90 (µm)

0.1

0.1
10

100

time, t (min)

Figure 3.3 Impact of polymer concentration: (a) the time-wise variation of the median
size (d50), (b) 90% passing size (d90) of NPX during milling.

Table 3.4 Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for NPX Suspensions After
Milling and After 7 days Storage
Run

Formulation

d50 (µm) ± SD

d90 (µm) ± SD

After Milling

7-Day Storage

After Milling

7-Day Storage

3

2.5% HPC SL, 0.5% SDS

0.110 ± 0.000

0.111 ± 0.001

0.185± 0.001

0.196± 0.005

4

0.5% PVP 17

0.124 ± 0.003

0.128 ± 0.000

0.215± 0.004

0.219± 0.000

5

2.5% PVP 17

0.126 ± 0.002

0.130 ± 0.003

0.206± 0.000

0.209± 0.000

7

5% PVP 17

0.135 ± 0.001

0.135 ± 0.001

0.212± 0.000

0.214± 0.001

8

10% PVP 17

0.139 ± 0.001

0.139 ± 0.001

0.222± 0.000

0.225± 0.001
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3.2.2 Apparent Shear Viscosity
In order to investigate the impact of PVP 17 concentration on the suspension rheology,
the apparent shear viscosity was obtained as a function of shear rate (Figure 3.4). HPCSDS was used as a baseline formulation to assess the performance of PVP at different
concentrations. All of the polymer solutions and the milled NPX suspensions has
apparent shear viscosity less than 6 cP at the maximum (Table 3.5), except the case of
HPC-SDS solution. Low viscosity (below 100 cP, preferably 50 cP) is critical for
injectable suspensions in mitigating the side effects and ensuring proper injections. The
slight shear thickening behavior may be due to inaccuracy of the instrument at low
viscosity region.

Apparent Shear Viscosity (cP)

100
0.5% PVP 17
2.5% PVP 17
5% PVP 17
10% PVP 17
2.5% HPC SL, 0.5% SDS

solutions

suspensions

10

1

0.5% PVP 17
2.5% PVP 17
5% PVP 17
10% PVP 17
2.5% HPC SL,
0.5% SDS
100

1000

100

1000

Shear rate (1/s)

Figure 3.4 Log–log plots for apparent shear viscosity versus shear rate for (a) the
PVP 17 solutions; (b) milled NPX suspensions.

33
Table 3.5 Apparent Shear Viscosity of Different Concentrations of PVP 17 Suspensions
at 25 °C and 1000 (1/s) Shear Rate
Run

Formulation

2.5% HPC SL, 0.5% SDS

Apparent Shear
Viscosity (cP)
(solution)
44.5

Apparent Shear
Viscosity (cP)
(milled suspension)
6.7

3
4

0.5% PVP 17

3.6

4.9

5

2.5% PVP 17

3.8

4.3

7

5% PVP 17

4.1

4.4

8

10% PVP 17

5.2

5.3

3.2.3 Surface Tension
In general, surface tension of the milled suspensions is higher than the stock solution for
all PVP 17 concentrations, as shown in Table 3.6. The higher surface tension in the
milled suspensions is probably due to the presence of a hydrophobic drug, absence of a
surfactant, and PVP adsorption on drug particle surfaces, so that less amount of PVP is
available in solution to reduce the suspension surface tension. Due to the presence of
SDS, the solution and the suspension had similar surface tension values for NPX
suspensions with HPC–SDS formulation, which had much lower surface tension than
PVP formulation.
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Table 3.6 Surface Tension for Different Concentrations of PVP 17 Suspensions
Run Formulation

Solution (mN/m)
Mean ± SD

Milled Suspension (mN/m)
Mean ± SD

3

37.838 ± 0.090

36.517 ± 0.564

2.5% HPC SL,
0.5% SDS

4

0.5% PVP 17

47.763 ± 0.133

57.218 ± 0.213

5

2.5% PVP 17

44.541 ± 0.115

52.027 ± 0.081

7

5% PVP 17

51.933 ± 0.255

56.751 ± 0.216

8

10% PVP 17

46.783 ± 0.044

55.255 ± 0.056

3.3 Impact of Different Polymers

3.3.1 Particle Size
Impact of different polymers on the stabilization of NPX drug particles was studied in
current section. The polymer concentration was fixed at 2.5% based on the optimized
PVP concentration. HPC-SDS was again used as a baseline. The evolution of both D50
and D90 exhibited a monotonic decrease for all polymers (Figure 3.5), except Soluplus.
When Soluplus was used as a stabilizer, the drug particle size fluctuated during milling
and the final particle size of D90 was above 1 µm. This suspension exhibited severe
aggregation. The final particle sizes shown in Table 3.7 show that PVP 12, PVP 17, HPC
SL, and HPMC E3 were all able to stabilize NPX nanoparticles without the use of a
surfactant. On the other hand, only PVP 12 and PVP 17 grades were acceptable for
injectable applications.
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Median Size, d (µm)

2.5%
2.5%
2.5%
2.5%
2.5%
2.5%

PVP 17
PVP 12
HPC SL
HPMC E3
SOLUPLUS
HPC SL,0.5% SDS

90

Particle Size, d (µm)

0.1
10

1

0.1

10

100

time, t (min)

Figure 3.5 Impact of different polymers on: (a) the time-wise variation of the median
size (d50), (b) the 90% passing size (d90) of NPX during milling.

Table 3.7 Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for Different Polymer
Suspensions After Milling and After 7 days Storage
Run

Formulation

d50 ± SD (µm)

d90 ± SD (µm)

After Milling

7-Day Storage

After Milling

7-Day Storage

3

2.5% HPC SL,
0.5% SDS

0.110 ± 0.000

0.111 ± 0.001

0.185 ± 0.001

0.196 ± 0.005

5

2.5% PVP 17

0.126 ±0.002

0.130 ± 0.003

0.206 ± 0.00

0.209 ± 0.000

6

2.5% PVP 12

0.131 ±0.000

0.131 ±0.001

0.210 ± 0.001

0.213 ± 0.001

9

2.5% HPC SL

0.135 ± 0.004

0.130 ± 0.000

0.201 ± 0.001

0.195 ± 0.001

10

2.5% HPMC E3

0.135 ± 0.005

0.118 ±0.001

0.192 ± 0.001

0.189 ± 0.001

11

2.5% SOLUPLUS

0.189 ± 0.020

0.135 ± 0.001

1.08 ± 0.756

0.213 ± 0.001
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3.3.2 Apparent Shear Viscosity
Viscosity measurement was conducted to all polymer solution and milled suspensions.
All the polymer solutions and milled suspensions show viscosity less than 8 cP at the

Apparent Shear Viscosity (cP)

maximum, except the case of HPC-SDS solution (Table 3.8).

suspensions

solutions

10

1
100
2.5% PVP 17
2.5% PVP 12
2.5% HPC SL
2.5% HPMC E3
2.5% SOLUPLUS
2.5% HPC SL,0.5% SDS

1000

100

1000

Shear rate (1/s)

Figure 3.6 Log–log plots for apparent shear viscosity versus shear rate for (a) the
solutions; (b) milled NPX suspensions.
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Table 3.8 Apparent Shear Viscosity of Different Polymer Suspensions at 25 °C and
1000 (1/s) Shear Rate
Run Formulation
Apparent Shear
Apparent Shear
Viscosity (cP)
Viscosity (cP)
(Solution)
(Milled Suspension)
3
2.5% HPC SL, 0.5%
44.5
6.7
SDS
5

2.5% PVP 17

3.8

4.3

6

2.5% PVP 12

3.5

4.3

9

2.5% HPC SL

7.6

4.9

10

2.5% HPMC E3

6.3

7.3

11

2.5% SOLUPLUS

3.7

4.9

3.3.3 Surface Tension

Table 3.9 shows that the surface tension of the milled suspension was higher than
the stock solution, where polymer was used as the sole stabilizer. The increase in
suspension surface tension is due to the polymers adsorption on drug particle surfaces, so
that less amount of polymer is available in solution to reduce the suspension surface
tension. In the cases of PVP 12 and PVP 17, it seems polymer with lower molecular
grade (PVP 12) is less capable in reducing surface tension.
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Table 3.9 Surface Tension for Different Polymer Suspensions
Run

Formulation

Solution
(mN/m)
Mean ± SD

Milled Suspension
(mN/m)
Mean ± SD

3

2.5% HPC SL,
0.5% SDS

37.838 ± 0.090

36.517 ± 0.564

5

2.5% PVP 17

44.540 ± 0.115

52.027 ± 0.081

6

2.5% PVP 12

52.559 ± 0.854

57.567 ± 0.292

9

2.5% HPC SL

42.227 ± 0.057

43.216 ± 0.088

10

2.5% HPMC E3

41.902 ± 0.087

46.266 ± 0.138

11

2.5% SOLUPLUS

43.231 ± 0.016

49.191 ± 0.366
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3.4 Impact of Surfactant Concentration

3.4.1 Particle Size
This part of the study focuses on the impact of an injection-acceptable surfactant, i.e.,
Poloxamer concentration on NPX nanoparticle stabilization. HPC-SDS was again used as
a baseline condition. Figure 3.7 shows that an optimum Poloxamer concentration exists to
stabilize NPX nanoparticles, which is 2.5%. At 0.5%, severe aggregation took place,
leading to the formation of coarse aggregates as large as 14 µm. Above 2.5%, an increase
in Poloxamer concentration increased the final NPX particle size achieved (Table 3.10).
However, all D90 values for the milled suspensions stabilized by Poloxamer were above
0.3 µm (Table 3.10), suggesting that Poloxamer was not as effective as PVP in stabilizing
the NPX particles. Particle sizes slightly increased after 7 days storage, especially for
Poloxamer with the lowest concentration. Therefore, 2.5% was selected as an optimum
concentration and applied to the rest of surfactant studies.
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0.5% P188
2.5% P188
5% P188
10% P188
2.5% HPC SL,
0.5% SDS

50

Median Size, d (µm)

10

1

10

90

Particle Size, d (µm)

0.1

1

0.1
10

100

time, t (min)
Figure 3.7 Impact of surfactant concentration: (a) the time-wise variation of the median
size (d50), (b) the 90% passing size (d90) of NPX during milling.

Table 3.10 Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for Surfactant Concentration
After Milling and After 7 Days Storage
Run

Formulation

d50 ± SD (µm)

d90 ± SD (µm)

After Milling

7-Day Storage

After Milling

7-Day Storage

3

2.5% HPC SL,
0.5% SDS

0.110 ± 0.000

0.111 ± 0.001

0.185 ± 0.001

0.196±0.005

12

0.5% P188

4.965 ± 5.422

6.251 ± 1.311

14.185 ± 5.017

18.487±0.815

13

2.5% P188

0.169 ± 0.009

0.162 ± 0.003

0.324 ± 0.019

0.315±0.006

14

5% P188

0.207 ± 0.085

0.248 ± 0.004

0.372 ± 0.038

0.398 ± 0.003

10% P188

0.308 ± 0.014

0.312 ± 0.003

0.462 ± 0.031

0.475 ± 0.026

15
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3.4.2 Apparent Shear Viscosity
Viscosity measurement was conducted on all surfactant solutions and milled suspensions.
All the surfactant solutions and milled suspensions show viscosity less than 7 cP at the
maximum, except the case of HPC-SDS solution (Table 3.11). An increase in Poloxamer
concentration increased the apparent shear viscosity in the presence or absence of the
milled NPX particles (Figure 3.8).

Apparent Shear Viscosity (cP)

100
solutions

suspensions

10

1

0.1
10

0.5% P188
2.5% P188
5% P188
10% P188
2.5% HPC SL, 0.5% SDS
100

1000 10

100

1000

Shear rate (1/s)
Figure 3.8 Log–log plots for apparent shear viscosity versus shear rate for (a) the P188
solutions; (b) milled NPX suspension
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Table 3.11 Apparent Shear Viscosity of Surfactant P188 Suspensions at 25 °C and 1000
(1/s) Shear Rate
Run
Formulation
Apparent Shear
Apparent Shear
Viscosity (cP)
Viscosity (cP)
(Solution)
(Milled Suspension)
3
2.5% HPC SL,
44.5
6.7
0.5% SDS
12

0.5% P188

3.1

4.4

13

2.5% P188

4.2

4.9

14

5% P188

5.1

5.1

15

10% P188

6.3

6.4

3.4.3 Surface Tension
Surface tensions of the milled suspension were higher than the stock solution in all the
cases (Table 3.12), where Poloxamer was used as the sole stabilizer. The increase in
suspension surface tension is due to the surfactant adsorption on drug particle surfaces, so
that less amount of surfactant is available in solution to reduce the suspension surface
tension. An increase in concentration of Poloxamer 188 consistently decreased the
surface tension of the stabilizer solutions and milled suspensions.
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Table 3.12 Surface Tension for Different Concentrations of P188 Suspensions
Run

Formulation

Solution (mN/m)
Mean ± SD

Milled Suspension (mN/m)
Mean ± SD

3

2.5% HPC SL,
0.5% SDS

37.838 ± 0.090

36.517 ± 0.564

12

0.5% P188

44.344 ± 0.147

68.691 ± 2.727

13

2.5% P188

44.524 ± 0.122

45.600 ± 0.131

14

5% P188

42.563 ± 0.046

43.260 ± 0.218

15

10% P188

41.279 ± 0.078

42.782 ± 0.128

3.5 Impact of Different Surfactants

3.5.1 Particle Size
The particle sizes in the nanosuspension for various injection-acceptable surfactants were
plotted as a function of milling time as shown in Figure 3.9. While unacceptable for
injection, HPC-SDS combination was used as a baseline formulation to stabilize NPX
drug nanoparticle with a minimum amount of aggregates in the system. Two FDA
approved injectable surfactants with two different molecular weights were investigated.
All formulations with surfactant as the sole stabilizer showed monotonic decrease in
particle sizes initially, followed by a light increase or decrease in D50 after 48 min. It is
shown that Poloxamer 188 outshines other surfactants at 2.5%, but it is still not sterile
filterable as it has a final particle size D90 above 220 nm (Table 3.13). The 7-day
stability values demonstrated the particle size growth of NPX particles, which can be
attributed to simple aggregation and possibly Ostwald ripening (Zu et al. 2014). Particle
sizes after 7-day storage slightly increased, especially for Tween 20 and Tween 80.

50

Median Size, d (µm)

46

90

Particle Size,d (µm)

0.1

1

0.1
10

100
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2.5%
2.5%
2.5%
2.5%
2.5%

P188
P407
TWEEN 20
TWEEN 80
HPC SL, 0.5% SDS

Figure 3.9 Impact of different surfactants on: (a) the time-wise variation of the median
size (d50), (b) the 90% passing size (d90) of NPX during milling.

Table 3.13 Particle Size and Standard Deviation (SD) Obtained from Laser Diffraction (LD) for Different Surfactants After
Milling and After 7 Days Storage
Run

Formulation

d50 ± SD (µm)

d90 ± SD (µm)

After milling

7-Day storage

After milling

7-Day storage

3

2.5% HPC SL,
0.5% SDS

0.110 ± 0.000

0.111 ± 0.001

0.185 ± 0.001

0.196 ± 0.005

13

2.5% P188

0.169 ± 0.009

0.162 ± 0.003

0.324 ± 0.019

0.315 ± 0.006

16

2.5% P407

0.275 ± 0.005

0.292 ± 0.006

0.417 ± 0.000

0.431 ± 0.001

17

2.5% Tween 20

0.342 ± 0.009

0.364 ± 0.004

0.499 ± 0.025

0.537 ± 0.007

19

2.5% Tween 80

0.164 ± 0.018

0.179 ± 0.069

0.389 ± 0.005

0.518 ± 0.075

47

48

3.5.2 Apparent Shear Viscosity
Viscosity measurement was conducted on all surfactant solutions and milled suspensions.
All the surfactant solutions and milled suspensions show viscosity less than 7 cP at the
maximum, except the case of HPC-SDS solution (Table 3.14).

Apparent Shear Viscosity (cP)

100
solutions

suspensions

10

1

0.1
10

2.5% P188
2.5% P407
2.5% TWEEN 20
2.5% TWEEN 80
2.5% HPC SL, 0.5% SDS
100

1000 10

100

1000

Shear rate (1/s)

Figure 3.10 Log–log plots for apparent shear viscosity versus shear rate for (a) different
surfactant solutions; (b) milled NPX suspensions.
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Table 3.14 Apparent Shear Viscosity of Different Surfactant Suspensions at 25°C and
1000 (1/s) Shear Rate
Run

Formulation

Apparent Shear
Viscosity (cP)
(Solution)
44.4

Apparent Shear
Viscosity (cP)
(Milled Suspension)
6.7

3

2.5% HPC SL,
0.5% SDS

13

2.5% P188

4.2

4.9

16

2.5% P407

4.4

4.5

17

2.5% Tween 20

3.4

3.6

19

2.5% Tween 80

3.0

3.6

3.5.3 Surface Tension
Surface tensions of the milled suspension were higher than the stock solution in all the
cases (Table 3.15). The increase in suspension surface tension is due to the surfactant
adsorption on drug particle surfaces, so that less surfactant is available in solution to
reduce the surface tension. Tween was more effective than Poloxamers in reducing the
surface tension.
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Table 3.15 Surface Tension for Different Surfactant Suspensions.
Run Formulation

Solution (mN/m)
Mean ± SD

Milled Suspension (mN/m)
Mean ± SD

3

2.5% HPC SL,
0.5% SDS

37.838 ± 0.090

36.517 ± 0.564

13

2.5% P188

44.524 ± 0.122

45.6 ± 0.131

16

2.5% P407

37.539 ± 0.028

37.938 ± 0.059

17

2.5% Tween 20

35.554 ± 0.273

35.132 ± 0.262

19

2.5% Tween 80

34.891 ± 0.442

34.58 ± 0.665

3.6 Sterile Filtration
Several stabilizers were identified to produce NPX nanoparticles less than 220 nm in D90.
The feasibility of sterile filtration was assessed here. Four membranes, cellulose acetate
(CA), polyethersulfone (PES), polyvinylidene fluoride (PVDF), and polyamide (PA)
were tested. The comparison of filtration results with four membranes is given in Table
3.16. For sterile-filterable suspensions, no significant change in particle size in the filtrate
vs. 7-day stored suspension was observed after filtration. For example, 2.5% HPC SL0.5% SDS formulation, which is a baseline formulation, is sterile filterable; however
HPC SL and SDS are not admissible by FDA (US Food and Drug Administration) for
injectable formulations. Therefore, this formulation cannot be used in intravenous
injectables. On the other hand, the highly versatile polyvinylpyrrolidone PVP 17 is
pharmaceutically acceptable by FDA and has diverse properties including its solubility in
water and in a broad range of liquid media, high chemical and thermal resistance, and
unique wetting, binding, and film-forming properties. Interestingly, the NPX
nanosuspension with 2.5% PVP 17 cannot be filtered; drug particles could not pass
through the membrane despite the fact that the nanosuspension had a D90 below 220 nm.
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Considering the failure of 2.5% PVP 17 to prove its sterile filterability, 0.5% SDS as a
favorable surfactant, was added to the same formulation for the filtration studies.
However, even a combination of 2.5% PVP 17-0.5% SDS could not allow passage of the
NPX nanoparticles through any of the membranes. NPX nanopaticles with HPC SL alone
could be sterile filtered through only two membranes (PES and PVDF). Such failures
have also been observed in previous literature because of various limitations listed below:


The particles of the membrane filters approximate the pore size of the filter
surface because of their surface-retention mechanism. Such particles stop up the
pores and prevent fluid flow (S.S. Block, 2001).



Not all the particles smaller than its pore size pass through the membrane filter.
Some of these particles are collected on the membrane surface, and some are
trapped in the tortuous capillaries themselves. If there are a sufficient number of
these smaller particles, a rapid buildup in pressure differential results (S.S. Block,
2001).

Table 3.16 Filtration Studies in Different Membranes for: a) 2.5% HPC SL-0.5% SDS, b) 2.5% K17, c) 2.5% HPC SL
d50 ± SD (µm)
d90 ± SD (µm)
Membrane
(0.22 μm)
After Filtration
7-Day Storage
After Filtration
7-Day Storage
a) 2.5% HPC SL-0.5% SDS
Cellulose Acetate
0.105 ± 0.001
0.107± 0.001
0.175 ± 0.002
0.177 ± 0.001
(CA)
Polyethersulfone
0.116 ± 0.002
0.111 ± 0.002
0.177 ± 0.001
0.18 ± 0.002
(PES)
Polyvinylidene
0.106 ± 0.001
0.107 ± 0.001
0.175 ± 0.001
0.177 ± 0.001
fluoride (PVDF)
Polyamide (PA)
0.104 ± 0.003
0.108 ± 0.003
0.175 ± 0.001
0.176 ± 0
b) 2.5% K17
Cellulose Acetate
(CA)
Polyethersulfone
(PES)
Polyvinylidene
fluoride (PVDF)

NF

NF

NF

NF

NF

NF

NF

NF

NF

NF

NF

NF

Polyamide (PA)
c) 2.5% HPC SL
Cellulose Acetate
(CA)
Polyethersulfone
(PES)
Polyvinylidene
fluoride (PVDF)

NF

NF

NF

NF

NF

NF

NF

NF

0.131 ± 0.000

0.133 ± 0.001

0.190 ± 0.000

0.190 ± 0.000

0.128 ± 0.003

0.135 ± 0.001

0.192 ± 0.001

0.192 ± 0.001

Polyamide (PA)
NF-Non-Filterable.

NF

NF

NF

NF
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3.7 SEM

Figure 3.11 shows the SEM image of as-received NPX particles and NPX
particles after milling (Run 5). SEM images of the unmilled and milled NPX particles
confirm the breakage of the NPX particles and formation of 50–250 nm primary particles.
NPX particles become smaller and more rounded upon milling. A comparison of particles
sizes based on laser diffraction measurement and SEM images suggests that NPX
nanoparticles were formed by breakage, but they aggregated to various extents in the
suspensions depending on the stabilizer used. Stabilizers allow proper wetting of the
hydrophobic drug surfaces, which can help to disperse aggregates formed during the
milling process (Kissa et al. 1999). Hence, both the laser diffraction and the SEM
imaging suggest that the PVP 17 stabilized suspension had relatively small extent of
aggregation and the dominant mechanism during the milling was breakage and not
aggregation.
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Figure 3.11 SEM images showing the evolution of NPX particle size and morphology
during Run 5: (a) as received (b) After 64 min milling. Run 5 refer to the use of 100 μm
YSZ beads at the intensified process conditions (tip speed: 11.7 m/s, and flow rate: 343
ml/min). Initially, the NPX particles have d50 = 14.645 ± 0.465 μm and d90 = 31.868 ±
1.143 μm (marker size: 200 nm, 10.00 k magnification).
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3.8 XRD

One concern for the wet media milling process is that the energetic process may
lead to transition in the crystalline state of drugs. Figure 3.12 presents the XRD
diffractograms of as-received NPX, physical mixture of NPX and 2.5% PVP 17, as well
as milled suspension of NPX and 2.5% PVP 17 after overnight drying. The characteristic
peaks of NPX appeared in all diffractograms without a broad halo after milling. As
compared to the as-received NPX pattern, a slight reduction in the NPX peak intensities
in the unmilled physical mixture is seen, which is due to dilution and surface coverage of
NPX particles by PVP 17. On comparing dried, milled suspension’s pattern with that of
the physical mixture, we note that the peak positions remained the same despite a
reduction in peak heights after milling, which can be attributed to defect formation and
accumulation during milling as well as the aforementioned dilution effect (Monteiro et al.
2013). While XRD cannot detect minor amount of amorphous phase due to indirect
inference, crystal orientation effects, and instrument-related intensity variations
(Venkatesh et al. 2001), the aforementioned XRD results overall suffice to show that the
crystalline state of NPX was largely preserved after milling.
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Figure 3.12 XRD diffractograms of as-received NPX, and unmilled physical mixture
(NPX and 2.5% PVP 17), and dried, milled suspensions prepared with 100 μm YSZ
beads for 64 min milling at the intensified process conditions (u= 11.7 m/s, and Q= 343
ml/min).

CHAPTER 4
SUMMARY AND CONCLUSION
Naproxen (NPX) suspensions with various stabilizers have been produced via wet stirred
media milling with the goal of achieving sterile-filterable drug nanosuspensions. Process
intensification with smaller beads led to formation of NPX nanoparticles faster. The
intensified process was then used to assess the impact of various stabilizers on the
aggregation and physical stability. A baseline stabilizer formulation, HPC-SDS, was used
as a baseline comparison, which led to D90 below 220 nm although it cannot be used for
injectables. While HPC, HPMC, and PVP were more effective than various surfactants in
stabilizing the NPX nanosuspensions, only PVP is acceptable for injectable application
by FDA. Severe aggregation was observed when injection-acceptable surfactants were
used especially at low concentration. The rheological characterization of the milled NPX
suspensions suggests that most milled suspensions had relatively low viscosity (less than
10 cP), which is highly desirable for injectables. The NPX nanosuspensions with D90
below 220 nm were filtered through four different types of membranes. The concept of
sterile filtration has been demonstrated with the HPC-SDS and HPC alone formulations;
yet they cannot be used in injectable applications. While PVP allowed for NPX
suspensions to have D90 below 220 nm, the respective nanosuspension cannot be sterilefiltered through any of the membrane materials. Hence, we found that while D90 below
220 nm is a necessary condition for sterile-filterability, but it is not sufficient. It is clear
that NPX nanoparticles and PVP interact with membrane surfaces in such a way to cause
blocking of the filters. Further research is required to understand such interactions toward
designing a filter/process which ensures successful sterile filtration of nanosuspensions.
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CHAPTER 5
FUTURE WORK
The current study has dealt with various challenges to render NPX nanosuspensions
sterile-filterable. The following topics or aspects are of major interest for future work:


A thorough literature search for identifying the FDA approved polymers–
surfactants and their concentration range



A thorough literature search for identifying the current and potential applications
of sterile-filterable drug nanosuspensions such as long-acting parenteral
suspensions



A thorough literature search for factors controlling the ultrafiltration process
adopted in other chemical process industries



Combination

of

various

polymers

and

surfactants

to

stabilize

NPX

nanosuspensions and assessment of the impact of this combination on sterile
filterability


Use of multiple drugs to generalize the approach adopted in this study



Pre-filtration of the drug suspensions to remove coarse aggregates prior to sterile
filtration with a 220 nm pore membrane filter



Impact of heat treatment of the filter/suspensions on the sterile filterability
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